期刊文献+

环丙沙星在老年下呼吸道感染患者中的群体药代动力学分析 被引量:4

Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection
原文传递
导出
摘要 目的 分析环丙沙星在老年下呼吸道感染患者中的群体药代动力学(PPK).方法 连续入选43例2012年3月至2014年6月在北京大学第三医院呼吸重症监护室(RICU)具有铜绿假单胞菌感染危险因素者的老年下呼吸道感染患者,根据患者病情予经验给药,环丙沙星200 mg静脉输注,1次/12 h,重症感染患者予400 mg静脉输注,1次/12 h.治疗3d达到血药稳态,于第4天给药开始后7个不同时间点(1、2、3、4、6、8、12 h)中留取2个以上时间点的血清标本,同时收集临床资料.高效液相色谱(HPLC)法检测血清药物浓度.使用非线性混合效应模型(NONMEM)7.3.0软件进行群体药代动力学(PPK)分析.结果 40例患者完成研究,年龄(78±9)岁,共检测环丙沙星血清药物浓度210份.使用二室模型对环丙沙星的血药浓度数据进行群体药代动力学分析,清除率和中央室表观分布容积V1的群体典型值为17.8 L/h、49.8 L.血肌酐显著影响清除率,公式为清除率=17.8×[1-0.001 3×(血肌酐-67)]× e^ηli ×0.659^n(当剂量为200 mg时,n=1,当剂量为400 mg时,n=0.ηi为个体间随机变异).清除率和V1在剂量为200 mg时,需要乘以系数0.659.单次给药剂量为200和400 mg时,血清峰浓度(Cmax)稳态值分别为(4.2±1.1)和(5.3±1.2)mg/L,血药谷浓度(Cmin)稳态值分别为(1.1±1.1)和(0.8±0.4) mg/L,24 h血清浓度-时间曲线下面积AUC0-24h分别为(45.5±28.1)和(47.2±11.3) mg·h· L^-1.结论 本研究中建立的环丙沙星PPK模型,可用于指导临床个体化给药.老年患者使用环丙沙星时,提高单次使用剂量为0.4g可以增加最高血药浓度,但在肾功能正常情况下,并不会引起药物潴留. Objective To analyse population pharmacokinetic (PPK) parameter values of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection.Methods Hospitalized in Respiratory Intensive Care Unit (RICU) due to severe lower respiratory tract infection and at high risks of Pseudomonas aeruginosa.43 consecutive elderly patients received an intravenous infusion of ciprofloxacin at a dose of 200/400 mg every 12/24 h empirically.Plasma samples were drawn from Day 4 and at 1,2,3,4,6,8 and 12 h after infusion.The serum concentrations of ciprofloxacin were determined by high-performance liquid chromatography (HPLC).Ciprofloxacin population pharmacokinetic analysis was conducted by the NONMEM 7.3.0 software.Results Forty patients aged (78 ±9) years completed the study.A total of 210 serum concentrations were detected.The mean values of clearance and volume of distribution (V1) were 17.8 L/h and 49.8 L respectively.The serum creatinine level influenced ciprofloxacin according to the equation:Clearance =17.8 × [1-0.001 3 × (serum creatinine-67)] × e^ηli × 0.659^n (at a dose of 200 mg,n =1,at a dose of 400 mg,n =0;ηi for inter individual random variation).The values of clearance and V1 were multiplied by 0.659 at a dose of 200 mg.At the doses of 200 and 400 mg,the maximum steady-state concentrations (Cmax) were (4.2 ± 1.1) and (5.3 ± 1.21) mg/L,the minimum steady-state concentrations (Cmin) (1.1 ± 1.1) and (0.8 ± 0.4) mg/L and the area under concentration-time curve measured in steady-state up to 24 h after dosing (AUC0-24 h) were (45.5 ± 28.1) and (47.2 ± 11.3) mg · h · L^-1 respectively.Conclusions The clearance of ciprofloxacin in elderly patients significantly decreases as compared with adult patients.Ciprofloxacin PPK model shows a significant influence of serum creatinine level on ciprofloxacin clearance.A single dose of 400 mg may increase serum drug concentration,but causes no in vivo drug retention.
出处 《中华医学杂志》 CAS CSCD 北大核心 2015年第20期1581-1585,共5页 National Medical Journal of China
基金 首都医学发展科研基金(2009-2025)
关键词 呼吸道感染 环丙沙星 老年人 药代动力学 Respiratory tract infection Ciprofloxacin Aged Pharmacokinetics
  • 相关文献

参考文献14

  • 1Alan M, Grolimund E, Kutz A, et al. Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: a 6-year prospective follow- up study[J]. J Intern Med, 2014, Dec 19. doi: 10. llll/joim. 12341. [ Et)ub ahead of orintl.
  • 2朱德妹,汪复,胡付品,蒋晓飞,倪语星,孙景勇,徐英春,张小江,胡云健,艾效曼,俞云松,杨青,孙自镛,陈中举,贾蓓,黄文祥,卓超,苏丹虹,魏莲花,吴玲,张朝霞,季萍,王传清,王爱敏,张泓,孔菁,徐元宏,沈继录,单斌,杜艳.2010年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2011,11(5):321-329. 被引量:651
  • 3王启,赵春江,王辉,俞云松,朱震宏,褚云卓,孙自镛,胡志东,徐修礼,廖康,徐英春,张莉滟,梅亚宁,杨滨,倪语星.2012年中国13家教学医院革兰阴性杆菌耐药监测分析[J].中华医学杂志,2013,93(18):1388-1396. 被引量:27
  • 4刘又宁,施毅.铜绿假单胞菌下呼吸道感染诊治专家共识[J].中华结核和呼吸杂志,2014,37(1):9-15. 被引量:366
  • 5Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinines[J]. Nephron, 1976, 16(1 ) : 31-41.
  • 6Ferrara AM, Fietta AM. New developments in antibacterial choice for lower respiratory tract infections in elderly patients [ J ]. Drugs Aging, 2004, 21 (3) : 167-186.
  • 7Zhao W, Hill H, Le Guellec C, et al. Population pharmacokinetics of cipmfloxacin in neonates and young infants less than three months of age[ J]. Antimierob Agents Chemother, 2014, 58 ( 11 ) : 6572-6580.
  • 8Adefurin A, Sammons H, Jacqz-Aigrain E, et al. Ciprofloxacin safety in paediatrics : a systematic review [ J ]. Arch Dis Child, 2011,96(9) : 874-880.
  • 9Conil JM, Georges B, de Lussy A, et al. Ciprofloxacin use in critically ill patients: pharmaeokinetie and pharmacodynamie approaches[ J~. Int J Antimicrob Agents, 2008, 32 (6) : 505- 510.
  • 10Khachman D, Conil JM, Georges B, et al. Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmaeokinetic- pharmacodynamic analysis and Monte Carlo simulations[ J]. J Antimierob Chemother, 2011, 66 (8) : 1798-1809.

二级参考文献44

  • 1胡必杰,魏丽,张秀珍,唐英春,倪语星,黎毅敏,郭纪全,胡云建,张扣兴,杨莉.医院获得性肺炎发病时间对病原构成影响的回顾性队列研究[J].中华结核和呼吸杂志,2005,28(2):112-116. 被引量:48
  • 2王辉,陈民钧,倪语星,陈冬梅,孙自庸,陈燕,赵旺胜,邹雄,俞云松,胡志东,黄心宏,徐英春,谢秀丽,褚云卓,王倩,梅亚宁,田彬,张蓓,孔庆莲,于秀娟,潘玉红.2003—2004年中国十家教学医院革兰阴性杆菌的耐药分析[J].中华检验医学杂志,2005,28(12):1295-1303. 被引量:236
  • 3刘又宁,陈民钧,赵铁梅,王辉,王睿,刘庆锋,蔡柏蔷,曹彬,孙铁英,胡云建,修清玉,周新,丁星,杨岚,卓建生,唐英春,张扣兴,梁德荣,吕晓菊,李胜歧,刘勇,俞云松,魏泽庆,应可净,赵峰,陈萍,侯晓娜.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8. 被引量:788
  • 4Arias CA,Murray BE.Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J].N Engl J Med,2009,360(5):439-443.
  • 5Clinical and Laboratory Standads Institute.Performance Standards for Antimicrobial Susceptibility Testing[S].Fifteenth Informational Supplement,2010,M100-S20 Vol 30 No.1.
  • 6Clinical and Laboratory Standads Institute Performance Standards for Antimicrobial Susceptibility Testing[S].Fifteenth Informational Supplement,2010,M100-S20-U Vol 30 No 15.
  • 7Clinical Laboratory Standard Institute.Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria[S].Approved Guideline M45-A,Vol.26 No.19,2006.
  • 8Wang P,Hu FP,Xiong ZZ,et al.Susceptibility of ESBL-Producing nterobacteriaceae with the New CLSI Breakpoints[J].J Clin Microbiol,2011,49(6):3127-3131.
  • 9Yang Q,Wang H,Sun H,et al.Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems:results from large hospital-based surveillance studies in China[J].Antimicrob Agents Chemother,2010,54(1):573-577.
  • 10Wang H.Guo P,Sun HL,et al.Molecular epidemiology of clinical isolates of carbapenem-resistant Acinerobacter spp from Chinese hospitals[J].Antimicrob Agents Chemother.2007,51(11):4022-4028.

共引文献1023

同被引文献19

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部